DVAX - Dynavax Technologies Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Dynavax Technologies Corporation

2929 Seventh Street
Suite 100
Berkeley, CA 94710
United States
510-848-5100
http://www.dynavax.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees249

Key Executives

NameTitlePayExercisedYear Born
Mr. David F. NovackInterim Co-Pres & Co-Principal Exec. Officer614.59kN/A1962
Dr. Dennis A. Carson Ph.D., M.D.Co-Founder, Director & Member of Scientific Advisory Board40kN/A1947
Mr. Michael S. OstrachCFO, Chief Bus. Officer & Sr. VP658.51kN/A1952
Dr. Robert L. CoffmanChief Scientific Officer & Sr. VP724.28kN/A1947
Dr. Robert JanssenChief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs656.81kN/A1954
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma. Dynavax Technologies Corporation has a collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Corporate Governance

Dynavax Technologies Corporation’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.